EUCTR2016-004660-19-DE进行中（未招募）1 期
CDK4/6 inhibition in locally advanced/metastatic chordoma - NCT-PMO-1601
niversity Hospital Heidelberg0 个研究点目标入组 43 人开始时间: 2017年8月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with locally advanced or metastatic chordoma with confirmed diagnosis in a reference pathology (with immunohistology for epithelial membrane antigen, S100, Brachyury, INI-1) not amenable to curative treatment with surgery or radiotherapy.
- •At least one measurable tumor lesion according to RECIST 1.1 criteria
- •Loss of p16 determined immunohistochemically or CDKN2A/B genomically, presence of CDK4/6 and RB1 determined immunohistochemically or by RNA sequencing.
- •Age = 18 years, no upper age limit
- •Availability of tissue blocks preferably not older than 12 months for immunohistologic assessment (if no adequate material is available, re-biopsy should be considered before entering the study)
- •Non-pregnant and non-nursing. Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (WOCBP is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 months).
- •Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or use a highly effective method of birth control (double barrier contraceptive method (IUD, condome), tubal ligation, or partner’s vasectomy) while on therapy and for 14 weeks after the last dose of therapy. Hormonal contraception alone is an inadequate method of birth control. Female patients must agree not to donate lactation during treatment and until 14 weeks after end of treatment.
- •Men must agree not to father a child and must use a latex condom during any sexual contact with WOCBP while receiving therapy and for 14 weeks after therapy is stopped, even if they have undergone successful vasectomy. Sperm donation is not permitted for the same time interval.
- •Signed written informed consent
- •Performance status = 2 according to ECOG/WHO criteria
- •Ability of patient to understand the character and individual consequences of clinical trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 43
排除标准
- •Prior treatment with palbociclib or known intolerance/allergy to the compound or any ingredient (acquired or hereditary).
- •Prior treatment with other CDK4/6 inhibitors
- •Co-therapy with strong/potent CYP3A inducers and/or inhibitors, (e.g., Clarithromycin, Indinavir, Itraconazol, Ketoconazol, Lopinavir/Ritonavir, Nefazodon, Nelfinavir, Posaconazol, Saquinavir, Telaprevir, Telithromycin, Voriconazol, and St. John’s Wort [Hypericum perforatum])) while on treatment with study drug.
- •Co-therapy with corticosteroids above 7.5 mg Prednisolone/Prednisone or 30 mg Hydrocortisone.
- •Anticancer treatment less than 2 weeks prior to study treatment
- •Organ insufficiency: creatinine clearance <30ml/min; total bilirubin > 1.5x upper normal serum level; AST > upper normal serum level ; abnormal blood counts; heart failure (New York Heart Association (NYHA) III/IV); uncontrolled hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or restrictive ventilation disorder
- •Clinical signs of active infection (>Grade 2 according to CTCAE version 5.0)
- •Patients with a currently active” second malignancy other than non-melanoma skin cancer. Patients are not considered to have a currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
- •Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
- •Known or suspected active alcohol or drug abuse
- •Known positivity for HIV, active HAV, HBV, or HCV infection
- •Cytopenia: platelets <100g/l, neutrophils <1.0g/l, hemoglobin <10.0g/dl
- •Corrected QT interval (QTcB) >470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes
- •Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
- •Participation in other ongoing interventional clinical trials (according to AMG) within 4 weeks prior to study treatment.
研究者
相似试验
已完成
2 期
CDK4/6 Inhibition in Locally Advanced/Metastatic ChordomaChordomaNCT03110744University Hospital Heidelberg43
尚未招募
不适用
Optimal therapeutic strategies with CDK4/6 inhibitors based on the real world evidence in patients with HR-positive/HER2-negative advanced and metastatic breast cancerHormone receptor positive HER2 negative advanced metastatic breast cancerJPRN-UMIN000051975Japan Breast Cancer Research Group(JBCRG)400
Unknown
1 期
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor MalignanciesAdvanced Solid Tumor MalignanciesNCT01522989Georgetown University37
招募中
不适用
Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational studybreast cancerJPRN-UMIN000035533Setouchi Breast Project Comprehensive Support Organization75
已完成
不适用
A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.Breast CancerNCT05770713Pfizer48